NextCure Inc. (NXTC)
NASDAQ: NXTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NXTC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.53M
- EPS (TTM)
- -$6.78
- Dividend yield
- None
- 52-week range
- 1.55 – 15.74
- Day range
- 6.45 – 6.96
- Volume / Avg
- 30.62K / 79.46K
- Beta
- —
- Shares outstanding
- 4.58M
52-week range
NXTC stock today
NextCure (NXTC) closed at $6.45 on Nov 20, down 4.87% (-$0.33), versus the S&P 500's 3.70% decline. Trading was light, with 30.62K shares changing hands, about 39% of the average daily volume. Shares are 59.0% below their 52-week high of $15.74, set on Nov 24, 2025 and 316.1% above the 52-week low of $1.55, in the middle of the past year's range.
NXTC is down 54.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.6%. NextCure has posted a net loss over the last twelve months (EPS of -$6.78), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NextCure
Company profileNextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael S. Richman MSBA
- Headquarters
- Baltimore, MD
- Employees
- 40
- IPO year
- 2019
- Website
- nextcure.com
Financial highlights
Full financialsNextCure reported a net loss of $55.8 million, compared with a loss of $55.7 million a year earlier. Diluted earnings per share came in at -$19.65.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-55.84M | $-55.65M | $-62.72M | $-74.73M | $-69.39M |
| EPS (diluted) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$20.00+210.08%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-1.67 vs $-0.90
- Surprise
- -85.56%
NXTC news
All NXTC news- NextCure, Inc. Announces Record Date and Distribution Date for Pre-Closing Distribution of Contingent Value RightsNasdaq
- NextCure, Inc. Receives Nasdaq Non-Compliance Notice on November 16, 2026NasdaqNXTC, BF.A
- NextCure Provides Business Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
NextCure peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SERSerina Therapeutics Inc. | 1.12 | -6.67% | $29.76M | vs NXTC |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs NXTC |
| RNTXRein Therapeutics Inc. | 0.3369 | -8.38% | $29.06M | vs NXTC |
| ATHEAlterity Therapeutics Limited ADR | 1.52 | -8.16% | $29.02M | vs NXTC |
| AYTUAytu BioPharma Inc. | 2.66 | 0.00% | $28.91M | vs NXTC |
| PMNProMIS Neurosciences Inc. | 3.16 | -1.56% | $28.43M | vs NXTC |
| EDSAEdesa Biotech Inc. | 2.00 | -8.05% | $27.02M | vs NXTC |
| NSRXNasus Pharma Ltd. | 2.29 | -10.20% | $26.82M | vs NXTC |
Indexes, lists and sector
NextCure stock FAQ
What is NextCure's stock price today?
NXTC last traded at $6.45 as of Nov 20, 4:00 PM EST, down 4.87% on the day. Prices are delayed at least 15 minutes.
Does NextCure pay a dividend?
No. NextCure does not currently pay a regular cash dividend.
Who is NextCure's CEO?
Mr. Michael S. Richman MSBA is the chief executive officer of NextCure Inc., which has about 40 employees.
Has NXTC ever split its stock?
Yes. The most recent NXTC stock split was a 1-for-12 split on Jul 14, 2025.
What is the NXTC 52-week high?
The 52-week high for NXTC is $15.74 and the 52-week low is $1.55. The stock is currently 59.0% below its high.